Publications by authors named "Alexander E Frey"
Background: Immunotherapy agents are approved for adjuvant treatment of stage III melanoma; however, evidence for survival benefit in early stage III disease is lacking. Current guidelines for adjuvant immunotherapy utilization in stage IIIA rely on clinician judgment, creating an opportunity for significant variation in prescribing patterns. This study aimed to characterize current immunotherapy practice variations and to compare patient outcomes for different prescribing practices in stage IIIA melanoma.
View Article and Find Full Text PDFArticle Synopsis
- Immunotherapy is increasingly used in terminal illnesses, but the rate of its initiation at the end of life (EOL) is unclear.
- A study analyzed data from over 240,000 patients with advanced cancer (melanoma, NSCLC, kidney cancer) to understand characteristics and trends in EOL-initiated immunotherapy.
- Findings show that EOL-I immunotherapy instances rose over time, with significant increases in treatments started within a month of death, particularly in patients with extensive metastatic involvement.
Background: Initiation of oncologic care is often delayed, yet little is known about delays in hepatopancreatobiliary (HPB) cancers or their impact. This retrospective cohort study describes trends in time to treatment initiation (TTI), assesses the association between TTI and survival, and identifies predictors of TTI in HPB cancers.
Methods: The National Cancer Database was queried for patients with cancers of the pancreas, liver, and bile ducts between 2004 and 2017.